1
|
The Role of Ghrelin in Anorexia Nervosa. Int J Mol Sci 2018; 19:ijms19072117. [PMID: 30037011 PMCID: PMC6073411 DOI: 10.3390/ijms19072117] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2018] [Revised: 07/11/2018] [Accepted: 07/17/2018] [Indexed: 12/26/2022] Open
Abstract
Ghrelin, a 28-amino acid peptide hormone expressed in X/A-like endocrine cells of the stomach, is the only known peripherally produced and centrally acting peptide that stimulates food intake and therefore attracted a lot of attention with one major focus on the treatment of conditions where an increased energy intake or body weight gain is desired. Anorexia nervosa is an eating disorder characterized by a pronounced reduction of body weight, a disturbed body image and hormonal alterations. Ghrelin signaling has been thoroughly investigated under conditions of anorexia nervosa. The present review will highlight these alterations of ghrelin in anorexia and discuss possible treatment strategies targeting ghrelin signaling. Lastly, gaps in knowledge will be mentioned to foster future research.
Collapse
|
2
|
François M, Barde S, Achamrah N, Breton J, do Rego JC, Coëffier M, Hökfelt T, Déchelotte P, Fetissov SO. The number of preproghrelin mRNA expressing cells is increased in mice with activity-based anorexia. Neuropeptides 2015; 51:17-23. [PMID: 25963530 DOI: 10.1016/j.npep.2015.04.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Revised: 03/02/2015] [Accepted: 04/16/2015] [Indexed: 12/30/2022]
Abstract
Plasma levels of ghrelin, an orexigenic peptide, are increased during conditions of chronic starvation, such as in patients with anorexia nervosa. However, it is not known whether such increase can be related to the number of preproghrelin mRNA-expressing cells in the stomach, and if chronic starvation may activate a tentative central ghrelin production. In this work, in situ hybridization technique was used to analyze the presence and number of preproghrelin mRNA-expressing cells in the stomach and the hypothalamus of mice with activity-based anorexia (ABA) induced by the combination of running wheel activity with progressive, during 10 days, feeding-time restriction (FTR) and compared with sedentary FTR, ABA pair-fed (PF) and ad libitum-fed control mice. All food-restricted mice lost more than 20% of body weight. Body weight loss was similar in ABA and PF mice, but it was more pronounced than in FTR mice. Food intake was also lower in ABA than in FTR mice. Preproghrelin mRNA-expressing cells in the stomach were increased proportionally to the body weight loss in all food-restricted groups with the highest number in ABA mice. No preproghrelin mRNA-producing cells were detectable in the hypothalamus of either control or food-restricted mice. Thus, the increased number of gastric preproghrelin mRNA-producing cells during chronic starvation proportionally to the body weight loss and reduced food intake may underlie increased plasma ghrelin. Hyperactivity-induced anorexia appears to further increase the number of preproghrelin mRNA-producing cells in the stomach. No evidence was found for ghrelin expression in the hypothalamus, not even in any of the present experimental models.
Collapse
Affiliation(s)
- Marie François
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, Rouen 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France
| | - Swapnali Barde
- Department of Neuroscience, Karolinska Institutet, Stockholm, 17177, Sweden
| | - Najate Achamrah
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, Rouen 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France; Department of Nutrition, Rouen University Hospital, CHU Charles Nicolle, Rouen, 76183, France
| | - Jonathan Breton
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, Rouen 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France
| | - Jean-Claude do Rego
- Animal Behavior Platform (SCAC), Rouen, 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France
| | - Moïse Coëffier
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, Rouen 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France; Department of Nutrition, Rouen University Hospital, CHU Charles Nicolle, Rouen, 76183, France
| | - Tomas Hökfelt
- Department of Neuroscience, Karolinska Institutet, Stockholm, 17177, Sweden
| | - Pierre Déchelotte
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, Rouen 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France; Department of Nutrition, Rouen University Hospital, CHU Charles Nicolle, Rouen, 76183, France
| | - Sergueï O Fetissov
- Inserm UMR1073, Nutrition, Gut and Brain Laboratory, Rouen 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), Rouen University, Normandy University, Rouen, 76183, France.
| |
Collapse
|